C.

human pharmaceuticals for the treatment of pulmonary diseases, pulmonary conditions, bronchoconstrictive diseases, bronchoconstrictive conditions; infectious diseases, neurological diseases and conditions, neuromuscular diseases and conditions, musculoskeletal disorders, and diseases and conditions associated with skeletal muscle dysfunction, skeletal muscle wasting, skeletal muscle atrophy, skeletal muscle weakness, metabolic diseases and disorders, diabetes, hypertension, vascular diseases, and diseases and conditions associated with dysfunction of non-muscle myosin